Single-Dose Therapy in the Management of Urinary Tract Infections in Children

Trometamol Salt of Fosfomycin versus Netilmicin: Randomized Multicenter Study in Children’s Lower Urinary Tract Infections

“…No side effects or laboratory abnormalities were reported (no evidence of systemic involvement or in volvement of blood, liver or kidney due to toxicity). Our preliminary data further confirm that single-dose therapy is a safe and effective way of treating infections of the lower urinary tract [5][6][7][8][9][10][11][12][13]. Our results show an efficacy of fosfomycin trometamol in these pathologies even when compared with an effective drug such as netil micin.…”

“…From our and other investigators' experiences [3,11,13], it also appears that a failure of single-dose therapy may be con sidered a determining factor leading to further and ap propriate investigations. …”

A Systematic Review of Single-Dose Aminoglycoside Therapy for Urinary Tract Infection: Is It Time To Resurrect an Old Strategy?

“…Among the studies with adequate data, the percentage of patients with sustained microbiologic cure at 30 days was 73.4% Ϯ 9.6%. Among the studies providing comparisons of cure rates for patients with and without urinary tract abnormalities (11,12,14,19,20), patients with anatomical abnormalities were less likely to have initial microbiologic cure (86.3% versus 96.9%, P Ͻ 0.01), and, among studies with adequate data, were less likely to have sustained microbiologic cure at 30 days (57.3% versus 87.5%, P Ͻ 0.001). There was no significant difference in microbiologic cure rate in a comparison of pediatric-only studies (11-13, 18, 20, 22) and adult-only studies (15,17,19) (95% microbiologic cure rate and 94% microbiologic cure rate, respectively; P Ͼ 0.05).…”